Tenax Therapeutics Achieves Major Milestone As USPTO Grants Notice Of Allowance For U.S. Patent Application Covering Use Of Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics has been granted a Notice of Allowance for a U.S. patent titled 'Levosimendan for Treating Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF).'
May 31, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tenax Therapeutics' granted patent for Levosimendan treatment may strengthen its intellectual property portfolio and boost investor confidence.
The granted patent for Levosimendan treatment directly pertains to Tenax Therapeutics' product pipeline. This strengthens the company's intellectual property portfolio and may lead to increased investor confidence in the company's ability to develop and commercialize the treatment, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100